摩根大通发表研究报告,指亚盛医药(06855.HK) 股价年内累涨约83%,与恒生医疗保健指数的强劲表现(年内累升约78%)同步。该行在最近举行的中美生物技术论坛与管理层讨论后,并考虑公司产品管线的最新进展,摩通更新了模型。该行继续看好公司的关键资产-“olverembatinib”和“lisaftoclax”,预计其将推动今年强劲的产品销售。摩通亦对“lisaftoclax”海外潜力的展望有所...
Source Link摩根大通发表研究报告,指亚盛医药(06855.HK) 股价年内累涨约83%,与恒生医疗保健指数的强劲表现(年内累升约78%)同步。该行在最近举行的中美生物技术论坛与管理层讨论后,并考虑公司产品管线的最新进展,摩通更新了模型。该行继续看好公司的关键资产-“olverembatinib”和“lisaftoclax”,预计其将推动今年强劲的产品销售。摩通亦对“lisaftoclax”海外潜力的展望有所...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.